We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+10.32%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$871M
AUM Growth
+$146M
Cap. Flow
+$118M
Cap. Flow %
13.5%
Top 10 Hldgs %
47.29%
Holding
141
New
32
Increased
44
Reduced
18
Closed
28

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$43.2M
2
BMY icon
Bristol-Myers Squibb
BMY
+$32M
3
VTRS icon
Viatris
VTRS
+$17.7M
4
ARGX icon
argenx
ARGX
+$12.1M
5
IMMU
Immunomedics Inc
IMMU
+$9.29M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$21.4M
2
AMGN icon
Amgen
AMGN
+$18.5M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$15.6M
4
BIIB icon
Biogen
BIIB
+$14.5M
5
PFE icon
Pfizer
PFE
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 75.17%
2 Technology 4.8%
3 Industrials 2.36%
4 Financials 1.58%
5 Materials 0.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRQR icon
26
ProQR Therapeutics
PRQR
$243M
$7.72M 0.89%
398,749
-95,000
-19% -$1.01M
SRRK icon
27
Scholar Rock
SRRK
$5.67B
$7.64M 0.88%
296,856
+12,859
+5% +$236K
RETA
28
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$7.58M 0.87%
92,719
-43,325
-32% -$3.05M
VRNT
29
DELISTED
Verint Systems
VRNT
$7.52M 0.86%
+294,697
New +$7.16M
CLSD
30
DELISTED
Clearside Biomedical
CLSD
$7.1M 0.82%
76,979
+5,731
+8% +$681K
ASND icon
31
Ascendis Pharma A/S
ASND
$16B
$6.57M 0.75%
92,673
+14,625
+19% +$1.01M
QURE icon
32
uniQure
QURE
$3.03B
$6.47M 0.74%
177,849
+25,359
+17% +$943K
MLNT
33
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$6.39M 0.73%
323,373
+126,475
+64% +$3.2M
SYRE icon
34
Spyre Therapeutics
SYRE
$8.54B
$6.25M 0.72%
26,124
+5,759
+28% +$1.35M
TVRD
35
Tvardi Therapeutics
TVRD
$19.7M
$6.13M 0.7%
+7,109
New +$5.13M
V icon
36
Visa
V
$684B
$6.06M 0.7%
40,401
– –
ARRY
37
DELISTED
Array Biopharma Inc
ARRY
$6M 0.69%
395,000
+55,196
+16% +$846K
BHVN
38
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$5.84M 0.67%
155,515
+18,127
+13% +$667K
SBBP
39
DELISTED
Strongbridge Biopharma plc.
SBBP
$5.72M 0.66%
1,179,010
+505,014
+75% +$2.58M
SEDG icon
40
SolarEdge
SEDG
$2.51B
$5.68M 0.65%
150,817
+101,869
+208% +$4.91M
QTTB icon
41
Q32 Bio
QTTB
$466M
$5.6M 0.64%
13,617
+5,737
+73% +$1.95M
WAB icon
42
Wabtec
WAB
$49.1B
$5.57M 0.64%
53,114
+6,550
+14% +$706K
MRTX
43
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.32M 0.61%
112,908
+98,573
+688% +$5.49M
IFF icon
44
International Flavors & Fragrances
IFF
$20.2B
$5.07M 0.58%
+36,450
New +$4.79M
MA icon
45
Mastercard
MA
$502B
$5.07M 0.58%
22,760
– –
PVLA
46
Palvella Therapeutics
PVLA
$1.99B
$5.07M 0.58%
11,309
+776
+7% +$337K
LRMR icon
47
Larimar Therapeutics
LRMR
$397M
$5.03M 0.58%
35,833
-4,167
-10% -$506K
XENE icon
48
Xenon Pharmaceuticals
XENE
$6.06B
$5.01M 0.58%
379,484
-59,550
-14% -$690K
KDMN
49
DELISTED
Kadmon Holdings, Inc.
KDMN
$4.98M 0.57%
1,490,000
-62,846
-4% -$223K
CSCO icon
50
Cisco
CSCO
$457B
$4.87M 0.56%
100,000
– –
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2018 Portfolio in Review

As of Q3 2018, Sphera Funds Management held 141 positions worth $871M, up 20% from $725M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sphera Funds Management deployed $118M of net new capital in Q3 2018, opening 32 new positions and adding to 44 existing holdings. Its largest new stake was Johnson & Johnson: 325,000 shares worth $44.9M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 72% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $15.6M trimmed.

  • Sphera Funds Management's largest Q3 2018 buy was Johnson & Johnson: 325,000 shares worth $44.9M.
  • Sphera Funds Management added most to Viatris in Q3 2018, an estimated $17.7M increase.
  • Sphera Funds Management's biggest Q3 2018 reduction was Alnylam Pharmaceuticals, cutting an estimated $15.6M.
  • Sphera Funds Management fully exited Shire pic in Q3 2018, selling an estimated $21.4M.
  • Sphera Funds Management's ten largest holdings make up 47% of its $871M portfolio in Q3 2018.
  • Sphera Funds Management opened 32 new positions and closed 28 in Q3 2018.
  • Sphera Funds Management's portfolio value rose 20% quarter-over-quarter to $871M.

Based on Sphera Funds Management's 13F filing for Q3 2018, filed 14 Nov 2018.